EZR and neoplasm: The tumor-free survival rates were significantly higher for patients with GCTB at Campanacci stages I and II than for those with GCTB at Campanacci stage III (P < 0.01, Figure 3A) while the tumor-free survival rate was obviously lower for ezrin (+ +) GCTB patients than for ezrin (−/+) GCTB patients (P < 0.01, Figure 3B).